title: [Nontuberculous mycobacterial pulmonary disease].
abstract: Nontuberculous mycobacteria (NTM) are a group of biologically diverse, ubiquitous and naturally multi-drug resistant bacteria with facultative pathogenicity. Recent data suggest that their clinical significance is increasing worldwide and that susceptible individuals may be at risk for infection via contaminated surfaces and aerosols. These individuals often have a predisposition for chronic respiratory diseases, e. g. bronchiectasis, chronic obstructive pulmonary disease (COPD) and cystic fibrosis and these conditions frequently share the same unspecific signs and symptoms with NTM pulmonary disease (NTM-PD). As a consequence, the diagnosis of NTM-PD, which is established based on clinical, radiological and microbiological criteria, is often delayed. Treating NTM-PD is more demanding than treating pulmonary tuberculosis as therapy is generally more tedious, toxic and expensive as well as being prone to failure. Patient and pathogen-specific factors guide the choice of an appropriate antimicrobial combination regimen, which should comply with national and international recommendations. Adverse events are common, should be anticipated and closely monitored. If infections with infrequently encountered mycobacterial species and severe or refractory disease occur, an interdisciplinary approach should be used, involving infectious disease specialists, experienced thoracic surgeons and referral to an NTM specialist center.
authors.affiliation: Klinik für Pneumologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland. ringshausen.felix@mh-hannover.de.|Deutsches Zentrum für Lungenforschung (DZL), Hannover, Deutschland. ringshausen.felix@mh-hannover.de.
authors.forename: F C
authors.initials: FC
authors.lastname: Ringshausen
authors.affiliation: Klinik für Pneumologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
authors.forename: J
authors.initials: J
authors.lastname: Rademacher
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D003937:Diagnosis, Differential; D019317:Evidence-Based Medicine; D006801:Humans; D008171:Lung Diseases / Q000175:diagnosis* / Q000188:drug therapy* / Q000382:microbiology; D009165:Mycobacterium Infections, Nontuberculous / Q000175:diagnosis* / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents
keywords: Azithromycin; Bronchiectasis; Cystic fibrosis; Ethambutol; Pulmonary disease, chronic obstructive
references.citation: Ann Am Thorac Soc. 2014 Jan;11(1):1-8
references.pmid: 24102151
references.citation: Eur Respir J. 2013 Dec;42(6):1604-13
references.pmid: 23598956
references.citation: Eur Heart J. 2015 Oct 21;36(40):2745-53
references.pmid: 26188001
references.citation: Ann Am Thorac Soc. 2014 Jan;11(1):30-5
references.pmid: 24460437
references.citation: Chest. 1992 Jun;101(6):1605-9
references.pmid: 1600780
references.citation: Chest. 2006 Feb;129(2):341-8
references.pmid: 16478850
references.citation: Ann Am Thorac Soc. 2015 May;12(5):642-7
references.pmid: 25692495
references.citation: Am J Respir Crit Care Med. 2012 Apr 15;185(8):881-6
references.pmid: 22312016
references.citation: F1000Prime Rep. 2014 Nov 04;6:107
references.pmid: 25580261
references.citation: J Antimicrob Chemother. 2014 Jul;69(7):1945-53
references.pmid: 24633206
references.citation: Eur Respir J. 2015 Apr;45(4):1177-9
references.pmid: 25614169
references.citation: Clin Infect Dis. 2001 Jun 1;32(11):1648-50
references.pmid: 11340540
references.citation: Antimicrob Agents Chemother. 2013 May;57(5):2281-5
references.pmid: 23478956
references.citation: Lancet. 2013 May 4;381(9877):1551-60
references.pmid: 23541540
references.citation: J Thorac Dis. 2014 Mar;6(3):210-20
references.pmid: 24624285
references.citation: Am J Respir Crit Care Med. 2012 Jan 15;185(2):231-2
references.pmid: 22246710
references.citation: Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416
references.pmid: 17277290
references.citation: Am J Respir Crit Care Med. 2012 Sep 15;186(6):553-8
references.pmid: 22773732
references.citation: Pneumologie. 2013 Nov;67(11):605-33
references.pmid: 24198237
references.citation: Emerg Infect Dis. 2013 Nov;19(11):1889-91
references.pmid: 24210012
references.citation: Thorax. 2016 Jan;71 Suppl 1:i1-22
references.pmid: 26666259
references.citation: J Clin Microbiol. 2013 Oct;51(10):3389-94
references.pmid: 23946523
references.citation: Lett Appl Microbiol. 2014 Jul;59(1):65-70
references.pmid: 24612016
references.citation: N Engl J Med. 2012 May 17;366(20):1881-90
references.pmid: 22591294
references.citation: Antimicrob Agents Chemother. 2012 Dec;56(12):6324-7
references.pmid: 23027189
references.citation: Am J Respir Crit Care Med. 2015 Jan 1;191(1):96-103
references.pmid: 25393520
references.citation: PLoS One. 2014 Mar 14;9(3):e91879
references.pmid: 24632814
references.citation: Emerg Infect Dis. 2010 Oct;16(10):1576-83
references.pmid: 20875283
references.citation: Clin Infect Dis. 2015 Jul 1;61(1):67-75
references.pmid: 25761866
references.citation: J Clin Microbiol. 2013 Jun;51(6):1747-52
references.pmid: 23536397
references.citation: Am J Respir Crit Care Med. 2012 Oct 1;186(7):684-91
references.pmid: 22859521
references.citation: Clin Infect Dis. 2015 Apr 1;60(7):1007-16
references.pmid: 25452595
references.citation: Emerg Infect Dis. 2009 Oct;15(10):1562-9
references.pmid: 19861046
references.citation: Future Microbiol. 2014;9(9):1095-110
references.pmid: 25340838
references.citation: Clin Chest Med. 2015 Mar;36(1):13-34
references.pmid: 25676516
references.citation: BMC Infect Dis. 2013 May 21;13:231
references.pmid: 23692867
references.citation: Curr Opin Infect Dis. 2012 Apr;25(2):218-27
references.pmid: 22327466
references.citation: Chest. 2015 Aug;148(2):499-506
references.pmid: 25675393
references.citation: Respirology. 2009 Jan;14(1):12-26
references.pmid: 19144045